Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00816764 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00816764 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 18 participants.
The verdict
NCT00816764, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is the first in human study of AGS-8M4 given every 2 weeks to subjects with advanced ovarian cancer. AGS-8M4 will be administered as an IV infusion until the disease worsens.
Interventions
- BIOLOGICAL AGS-8M4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00816764
The ClinicalTrials.gov registry entry for NCT00816764 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AGS-8M4 is the first listed.
NCT00816764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00816764 about?
NCT00816764 is a clinical study titled "A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer". This is the first in human study of AGS-8M4 given every 2 weeks to subjects with advanced ovarian cancer. AGS-8M4 will be administered as an IV infusion until the disease worsens.
What is the current status of trial NCT00816764?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2008-10. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00816764?
The interventions under investigation include: AGS-8M4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00816764?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.